Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

(182)Interest expense54 ,299 Other expense33 Income taxes(3,848)47 Less amount attributable to noncontrolling interest(6,273)(34,119)47,794 92,428 ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$
479,923 $
338,497 BASIC ADJUSTED INCOME PER COMMON SHARE

$
.39 $
4.73 DILUTED ADJUSTED INCOME PER COMMON SHARE

$
5.94 $
4.36 WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING

75,12871,541WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION80,761 77,552 * Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($89.4M in 2010; $70.6M in 2009), accelerated depreciation related to restructuring ($14.9M in 2010; $14.0M in 2009), amortization of inventory revaluation related to Mepha ($10.5M in 2010) and the write-off of modafinil purchase commitments in excess of estimated requirements ($9.4M in 2010; $3.0M in 2009), offset by the gain recognized in connection with an agreement to reduce our excess modafinil purchase commitments ($9.5M in 2009).(2) To exclude accelerated depreciation related to restructuring ($0.7M in 2010; $0.9M in 2009), the impairment of an investment ($2.0M in 2010), charges related to payments for several research and development collaborations ($2.0M in 2009) and charges related to our transaction with Arana Therapeutics Limited ($1.5M in 2009).(3) In 2010, to exclude charges related to the acquisition of Mepha ($10.3M), the acquisition of Ception noncontrolling interest ($1.4M), offset by proceeds related to the settlement of litigation in Europe ($2.1M).  In 2009, to exclude charges related to the acquisition of Arana Therapeutics Limited ($7.8M) and charges related to our settlement with Takeda ($6.5M) to resolve our remaining contractual arrangements.  (4) To exclude the
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Bioactive Small Molecules through ... ... today announced the addition of 1,300 bioactive small molecules to,its ... provides expanded data on the functional relationship between,bioactive small molecules ...
... Enable Healthcare ... Providers Access to PET Technology, HOFFMAN ... today announced its first molecular imaging,biomarker production facility in ... in and around Chennai to access the,positron emission tomography-computed ...
... Burke, MD, Executive Vice,President and Physician-in-Chief at The ... elected the 40th President of the Society of,Gynecologic ... March 9-12, 2008 in Tampa, Florida., Dr. ... Tulane,University in New Orleans, Louisiana. He served both ...
Cached Biology Technology:Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool 2Siemens to Launch PETNET Services in India 2Siemens to Launch PETNET Services in India 3Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
(Date:4/23/2014)... by a University of Exeter researcher has shed light ... camels thriving in Australia,s remote outback have become reviled ... Sarah Crowley, of the Environment and Sustainability Institute at ... of the camel in Australia, from their historic role ... current status as unwelcome "invader." , The deserts of ...
(Date:4/23/2014)... one can argue that if we were to follow a ... we canthen we can solve the climate problem without doing ... climate researchers, in the current issue of Bulletin of ... significant action on climate change now makes it more likely ... Wigley explains in an exclusive Bulletin interview. ...
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2Scientists identify critical new protein complex involved in learning and memory 2
... 5, 2013 What can the U.S. military learn from ... enemies, according to researchers at UC Irvine,s Henry Samueli School ... in Advanced Materials , they have created a biomimetic ... squids or your everyday calamari. Led by Alon Gorodetsky, ...
... announced today in Milan by the Chairman of the ... President of the Balzan "Prize" Foundation, Ambassador Bruno Bottai, ... profiles of the winners and the citations (the Prizes ... held in Bern on November 15) were presented by ...
... , September 9, 2013 Cytos Biotechnology Ltd ... trial with CYT003, a first-in-class immune modulator in clinical development ... analysis of data published in the March issue of ... presented today at the European Respiratory Society Annual Congress in ...
Cached Biology News:UCI researchers fabricate new camouflage coating from squid protein 22013 Balzan prizewinners announced today in press conference in Milan 22013 Balzan prizewinners announced today in press conference in Milan 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
... Kit for Kilo-Sequencing is designed to aid ... into the multiple cloning sites (MCS) of ... or phagemid vectors (pUC18/19). The kit is ... the target DNA, thereby progressively moving the ...
... Freezerworks Unlimited includes 2 clients and streamlines sample ... sharing of freezers by multiple groups without the ... Network Client/Server version for Macintosh ... with 256 colors; OS 8.6 & OS 9.x ...
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: